发布求助
文献互助 智能选刊 最新文献

Clinical pharmacology and therapy最新文献

筛选
英文 中文
Glucocorticoids in systemic lupus erythematosus: future of steroid-sparing therapy 糖皮质激素治疗系统性红斑狼疮:类固醇保留治疗的未来
Clinical pharmacology and therapy Pub Date : 2022-11-03 DOI: 10.32756/0869-5490-2022-4-18-27
P. Novikov, S. Moiseev
{"title":"Glucocorticoids in systemic lupus erythematosus: future of steroid-sparing therapy","authors":"P. Novikov, S. Moiseev","doi":"10.32756/0869-5490-2022-4-18-27","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-18-27","url":null,"abstract":"The isolation of glucocorticoids (GC) was a tremendous achievement in the history of medicine and had a clinical impact similar to that of the discovery of insulin or antibiotics. However, with the expansion of their use, multiple side effects have become evident even patients treated with low doses. GC remain one of the main agents in the treatment of systemic lupus erythematosus (SLE). The studies of genomic and nongenomic effects of GC justified their use in lower starting doses (e.g. 30 to 40 mg daily) even in patiens with lupus nephritis. Methylprednisolone pulses and early initiation of hydroxychloroquine and immunosuppressive agents may allow more rapid tapering and discontinuation of GC in SLE patients. Development of novel steroid-sparing agents, e.g. anifrolumab, a monoclonal antibody to interferon I receptor, or voclosporin, an oral calcineurin inhibitor, may result in further improvement in the efficacy and safety of treatment.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87990625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Efficacy and safety of long-term enzyme replacement therapy with agalsidase alfa or agalsidase beta in adult patients with Fabry disease 成年法布里病患者长期用琼脂苷酶或琼脂苷酶替代治疗的疗效和安全性
Clinical pharmacology and therapy Pub Date : 2022-11-03 DOI: 10.32756/0869-5490-2022-4-28-34
A. Moiseev, N. Bulanov, E. Tao, E. Mershina, V. Sholomova, S. Moiseev
{"title":"Efficacy and safety of long-term enzyme replacement therapy with agalsidase alfa or agalsidase beta in adult patients with Fabry disease","authors":"A. Moiseev, N. Bulanov, E. Tao, E. Mershina, V. Sholomova, S. Moiseev","doi":"10.32756/0869-5490-2022-4-28-34","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-28-34","url":null,"abstract":"To evaluate the efficacy and safety of long-term enzyme replacement therapy (ERT) in the Russian population of patients with Fabry disease (FD).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79087106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-inflammatory effect of anakinra, an interleukin-1 receptor inhibitor, in patients with refractory tophaceous gout 白介素-1受体抑制剂anakinra在难治性痛风患者中的抗炎作用
Clinical pharmacology and therapy Pub Date : 2022-11-03 DOI: 10.32756/0869-5490-2022-4-48-50
I. N. Schendrigin, S. Piskov
{"title":"Anti-inflammatory effect of anakinra, an interleukin-1 receptor inhibitor, in patients with refractory tophaceous gout","authors":"I. N. Schendrigin, S. Piskov","doi":"10.32756/0869-5490-2022-4-48-50","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-48-50","url":null,"abstract":"The first line treatments for acute gouty arthritis are nonsteroidal anti-inflammatory drugs (NSAID), corticosteroids, and colchicine. However, these agents are ineffective or contraindicated in a proportion of patients. Interleukin (IL)-1 is a key mediator in the pathogenesis of acute gouty arthritis. Recently, three IL-1-targeted agents have been developed, including anakinra, the IL-1 receptor antagonist. The authors present two patients with a flare of refractory tophaceous gout who were treated with anakinra.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80855410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autoimmunity, autoinflammation and kidney 自身免疫，自身炎症和肾脏
Clinical pharmacology and therapy Pub Date : 2022-11-03 DOI: 10.32756/0869-5490-2022-4-7-17
S. Moiseev, N. Bulanov
{"title":"Autoimmunity, autoinflammation and kidney","authors":"S. Moiseev, N. Bulanov","doi":"10.32756/0869-5490-2022-4-7-17","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-7-17","url":null,"abstract":"Systemic autoimmune and autoinflammatory disease are associated with all types of diffuse kidney disease, that is, glomerulonephritis (including rapidly progressive), thrombotic microangiopathy, tubulointerstitial nephritis, and AA-amyloidosis. However, the occurrence and types of nephropathies differ significantly in patients with various systemic immunemediated inflammatory diseases. For example, glomerulonephritis is one of the leading manifestation of systemic lupus erythematosus and small-vessels vasculitis, thrombotic angiopathy occurs frequently in patients with both primary and secondary antiphosholipid syndrome, tubulointerstitial nephritis is frequently found in patients with Sjogren syndrome and IgG4-associated disease, whereas AA-amyloidosis can complicate rheumatoid arthritis, ankylosing spondilytis, psoriatic arthritis, familial Meditarranean fever, and certain other monogenic autoinflammatory diseases. Over last decades, renal survival in patients with autoimmune and autoinflammatory diseases improved significantly due to earlier diagnosis and development of effective immunosuppressive and anti-inflammatory treatments. However, a proportion of patients still present with progressive impairment of kidney function that can be unrelated to activity of underlying diseases.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89270238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practical issues in the use of levilimab, a novel interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis 在类风湿关节炎患者中使用一种新型白细胞介素-6受体抑制剂来利单抗的实际问题
Clinical pharmacology and therapy Pub Date : 2022-11-03 DOI: 10.32756/0869-5490-2022-4-40-47
P. Novikov, E. Kuznetsova, N. Nosova, T. Shevtsova, M. Litvinova, V. Logina, S. Moiseev
{"title":"Practical issues in the use of levilimab, a novel interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis","authors":"P. Novikov, E. Kuznetsova, N. Nosova, T. Shevtsova, M. Litvinova, V. Logina, S. Moiseev","doi":"10.32756/0869-5490-2022-4-40-47","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-40-47","url":null,"abstract":"Levilimab is a monoclonal antibody targeting interleukin-6 receptors and having a potent anti-inflammatory activity. Efficacy and safety of levilimab for treatment of rheumatoid arthritis were established in multicenter, double blind, placebo-controlled clinical trials AURORA and SOLAR. The authors present two patients with rheumatoid arthritis who were treated successfully with levilimab and discuss various issues of its use in clinical practice.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78906346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug-induced rheumatological syndromes 药物引起的风湿病综合征
Clinical pharmacology and therapy Pub Date : 2022-11-03 DOI: 10.32756/0869-5490-2022-4-51-60
N. V. Bunchuk
{"title":"Drug-induced rheumatological syndromes","authors":"N. V. Bunchuk","doi":"10.32756/0869-5490-2022-4-51-60","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-51-60","url":null,"abstract":"An article reviews occurence, mechanism and treatment of drug induced reactions that resemble certain idiopathic rheumatic diseases and syndromes or are indistinguishable from them, that is, drug-induced lupus erythematosus, hyperuricemia and gout, osteopathy, statin-induced skeletal muscle damage, fluoroquinolone-induced tendinopathy, and autoimmune and inflammatory syndromes induced by checkpoint inhibitors.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80512417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Musculoskeletal pain: diagnostic issues and treatment 肌肉骨骼疼痛:诊断问题和治疗
Clinical pharmacology and therapy Pub Date : 2022-11-03 DOI: 10.32756/0869-5490-2022-4-61-64
L. V. Klimov
{"title":"Musculoskeletal pain: diagnostic issues and treatment","authors":"L. V. Klimov","doi":"10.32756/0869-5490-2022-4-61-64","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-61-64","url":null,"abstract":"Musculoskeletal pain is one of the main manifestations of joint and spine diseases. Chronic pain poses an enormous burden for patients, society and health care system. Patient with musculoskeletal pain requires multimodal therapy. Risk factors for chronic pain should be identified using biopsycho social model. Review article presents approaches to treatment of musculoskeletal pain.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84806973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interaction between rs4073 IL-8 gene polymorphism, serum IL-8 and development of alcoholic hepatitis rs4073 IL-8基因多态性、血清IL-8与酒精性肝炎发生的相互作用
Clinical pharmacology and therapy Pub Date : 2022-11-03 DOI: 10.32756/0869-5490-2022-4-35-39
O. Arisheva, A. Ivanov, I. Garmash, L. Goreva, M. Markova, S. Avdoshina, N. N. Terebilina, S. Pirozhkov, V. Baronets, D. I. Peregud, Z. Kobalava
{"title":"Interaction between rs4073 IL-8 gene polymorphism, serum IL-8 and development of alcoholic hepatitis","authors":"O. Arisheva, A. Ivanov, I. Garmash, L. Goreva, M. Markova, S. Avdoshina, N. N. Terebilina, S. Pirozhkov, V. Baronets, D. I. Peregud, Z. Kobalava","doi":"10.32756/0869-5490-2022-4-35-39","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-35-39","url":null,"abstract":"To study the interrelations between the rs4073 polymorphism of the IL-8 gene, IL-8 serum levels and severity of alcoholic hepatitis (AH).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78225264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The drug resistance index as an indicator for the impact of antimicrobial stewardship program implementation 将耐药指数作为衡量抗菌药物管理规划实施效果的指标
Clinical pharmacology and therapy Pub Date : 2022-09-12 DOI: 10.32756/0869-5490-2022-3-67-73
K. Karnoukh, E. Shikh, N. Lazareva
{"title":"The drug resistance index as an indicator for the impact of antimicrobial stewardship program implementation","authors":"K. Karnoukh, E. Shikh, N. Lazareva","doi":"10.32756/0869-5490-2022-3-67-73","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-67-73","url":null,"abstract":"To assess the changes in the drug resistance index (DRI), a composite measure that combines the level of resistance of individual pathogens with the extent of antimicrobial drugs consumption in a multidisciplinary hospital, after implementation of the antimicrobial stewardship program (AMSP) and during COVID-19 pandemic.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"612 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77355892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New prospects for drug treatment of chronic cerebral ischemia from the standpoint of neuroinflammation 从神经炎症的角度看慢性脑缺血药物治疗的新前景
Clinical pharmacology and therapy Pub Date : 2022-09-12 DOI: 10.32756/0869-5490-2022-3-4-8
I. N. Samartsev, S. A. Zhivolupov
{"title":"New prospects for drug treatment of chronic cerebral ischemia from the standpoint of neuroinflammation","authors":"I. N. Samartsev, S. A. Zhivolupov","doi":"10.32756/0869-5490-2022-3-4-8","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-4-8","url":null,"abstract":"The high prevalence of stroke worldwide requires a revision of the modern doctrine of the management of patients with cerebrovascular disease. It is obvious that only aggressive modification of risk factors for vascular pathology does not guarantee the prevention of acute cerebrovascular accident, which is an intermediate or final stage of cerebrovascular disease. In this regard, the use of neuroprotectors, including vinpocetine, can increase the tolerance of brain tissue to hypoxia. Vinpocetine, a derivative of the alkaloid vincamine, inhibiting phosphodiesterase and voltage-dependent Na+- channels is widely used in many countries for the treatment of cerebrovascular diseases, including chronic cerebral ischemia. Recent studies have identified a number of new therapeutic effects of vinpocetine, including stimulation of neuroplasticity via brain-derived neurotrophic factor and inhibition of neuroinflammation. The latter mechanism is mediated by the effect on NF-kB that suppresses the expression of NF-kBdependent pro-inflammatory molecules and prevents the formation of NLRP3 inflammasome. New data allow to reconsider the place of vinpocetine in the prevention and treatment of cerebrovascular disorders, and to recommend its use in a wide range of patients with chronic cerebral ischemia.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91540088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信